KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Precision palliative care in advanced/recurrent esophageal cancer patients treated with anti-PD-1/PD-L1 immunotherapy (ESO-Shanghai 25): a randomized, phase III Trial.

Shengnan Hao, Xiaomin Wang, Huiping Ding, Yun Chen, Qi Liu, Junhua Zhang, Xingwen Fan, Zhenhua Wu, Ying Lin, Xiaofang Xu, Guangmin Mao, Dashan Ai, Jiaying Deng, Hongcheng Zhu, Jinjun Ye, Miao Mo, Zhihuang Hu, Huijie Wang, Wenwu Cheng, Wei Feng, Yiqun Ling, Yufen Xu, Shisuo Du, Jialei Wang, Kuaile Zhao

Future Oncol 22(7) 773-780

PMID41778625
PMCIDPMC12977270
DOI10.1080/14796694.2026.2637738
发表日期2026-03-04
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 1 张 PMC Figure,均未识别为 KM 图:Figure 1.:生活质量量表图。
摘要

摘要

Over half of patients with advanced or recurrent esophageal cancer experience malnutrition, psychological distress, and cancer-related pain, which impair immune function, diminish quality of life, and attenuate responses to immunotherapy. Whether a precision palliative care (PC) model that integrates nutritional, psychological, and symptomatic support can improve survival and quality of life in these patients undergoing anti-PD-1/PD-L1 immunotherapy remains unknown. We are conducting a multicenter randomized trial to evaluate the superiority of a precision PC model compared with standard oncology care in improving patients' overall survival (OS). All patients will be randomly assigned to either the Standard Arm (standard oncology care)or the Precision Arm (standard oncology care + precision PC). Patients in the Standard Arm receive anti-PD-1/PD-L1 immunotherapy-based standard oncology care. Patients assigned to the Precision Arm receive anti-PD-1/PD-L1 immunotherapy-based standard oncologic care and precision PC, in which patients meeting any of the following criteria are stepped up to meet with the precision PC clinicians every 4 weeks: (1) malnutrition (NRS2002 ≥ 3 or meeting GLIM criteria), (2) psychological distress (GAD-7 ≥ 5 or PHQ-9 ≥ 5), or (3) moderate-to-severe symptoms (any MDASI symptom score ≥4). The primary endpoint is overall survival (OS). The secondary endpoints are quality of life and progression-free survival (PFS).Clinical trial registration: NCT06787313 (clinicaltrials.gov).

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(1,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1.Design of the ESO-Shanghai 25 trial. Standard oncology care is anti-PD-1/PD-L1 immunotherapy-based treatment, with or without chemotherapy. Precision palliative care is provided by the precision PC team and is initiated once a patient’s assessment score reaches (1) NRS 2002 ≥ 3 or malnutrition (GLIM), or (2) PHQ-9 ≥ 5 or GAD-7 ≥ 5, or (3) any symptom in MDASI ≥4. Abbreviation: NRS 2002, Nutritional Risk Screening 2002; GLIM, Global Leadership Initiative on Malnutrition; PHQ-9, Patient Health Questionnaire-9; GAD-7, Generalized Anxiety Disorder-7; MDASI, The MD Anderson Symptom Inventory; QOL, quality of life.
非 KM Figure